nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-AAD44C03·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Pathology and Forensic Medicine·Basis: Full text·Type: Prediction or prognostic modeling

A novel multiplexed biomarker panel reveals key molecular pathways in progressive multiple sclerosis.

Heiss et al.Heiss, Novakova, Axelsson et al.·2026·Brain communications·10.1093/braincomms/fcag142 ↗

Primary claim

Among RRMS patients, low baseline CSF concentrations of KIT ligand (KITLG) predicted both conversion to SPMS and future PIRMA events.

Tentative · small overlapping outcome groups, an internally derived cut-off, event-poor adjusted models, and no external validation
In brief

Longitudinal multiplex proteomics nominates KITLG and plasma cytokines as progression markers in multiple sclerosis, but internal model selection and reporting inconsistencies limit confidence.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

Progressive multiple sclerosis is characterized by gradual neurological decline, often occurring independently of relapses or MRI activity-a phenomenon known as progression independent of relapse and MRI activity (PIRMA). Despite the effectiveness of disease-modifying therapies in controlling inflammatory activity, identifying individuals at risk of PIRMA remains an unmet clinical need. The objective of this exploratory study was to identify biomarkers and underlying molecular pathways associated with multiple sclerosis progression and especially PIRMA. Using the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) inflammatory panel, we quantified 250 immune-related proteins in CSF and plasma from 49 controls, 49 patients with early active relapsing-remitting multiple sclerosis (RRMS) and 33 patients with inactive progressive multiple sclerosis (iPMS). Longitudinal clinical data were used to define PIRMA and conversion to secondary progressive multiple sclerosis (SPMS). We identified distinct proteomic signatures in CSF of both RRMS and iPMS patients compared with controls, with no significant differences in plasma. Both were associated with elevated markers of adaptive immunity, while iPMS showed a shift towards innate immune markers. Among RRMS patients, low baseline CSF concentrations of KIT ligand (KITLG) predicted both conversion to SPMS and future PIRMA events. Receiver operating characteristic analysis demonstrated KITLG's potential as a prognostic biomarker. Additionally, plasma concentrations of interleukin 1 beta and 36 gamma were elevated in RRMS patients who later developed SPMS. A model selection analysis identified a two-protein logistic regression model including interleukin 1 beta and interleukin 36 gamma as the best-performing combination (area under the curve = 0.990). Our findings reveal distinct immunological profiles across multiple sclerosis subtypes and identify KITLG as a promising biomarker for predicting disease progression and PIRMA. These results highlight potential targets for therapeutic intervention and demonstrate the utility of NULISA in uncovering novel molecular signatures in multiple sclerosis.

Key Claims

Primary finding · Tentative

Among RRMS patients, low baseline CSF concentrations of KIT ligand (KITLG) predicted both conversion to SPMS and future PIRMA events.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

small overlapping outcome groups, an internally derived cut-off, event-poor adjusted models, and no external validation

Abstract; Results, Fig. 4
Quote verified
Secondary · Supported

We identified distinct proteomic signatures in CSF of both RRMS and iPMS patients compared with controls, with no significant differences in plasma.

FDR-controlled adjusted CSF comparisons support the direction, while the small plasma sample limits confidence in the null result

Abstract; Results, Fig. 1–2
Quote verified
Secondary · Tentative

A model selection analysis identified a two-protein logistic regression model including interleukin 1 beta and interleukin 36 gamma as the best-performing combination (area under the curve = 0.990).

the apparent AUC follows selection in a very small cohort without cross-validation and duplicates another model’s reported statistics

Abstract; Results, Fig. 5C
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Long follow-up links baseline biomarkers

Baseline samples from untreated RRMS patients are connected to a median nine years of follow-up, including SPMS conversion and sustained PIRMA outcomes.

↳ Methods, Patients and Samples; Results, Fig. 4

#methodological rigour

Standardized sampling and multiplicity control

Samples followed the BioMS-EU handling protocol, and differential-expression analyses used age- and sex-adjusted models with FDR correction.

↳ Methods, NULISA Proteomic Analysis and Statistical Analysis

#positioning

Prior proteomic evidence is engaged

The Discussion compares the findings with prior CSF signatures and a large plasma proteomic study that reported broader alterations, rather than presenting the results in isolation.

↳ Discussion, first two paragraphs

Limitations

#reporting

Potentially duplicated headline model statistics

The IL1B–IL36G SPMS model and the CCL27–NGF–SPP1 PIRMA model report exactly the same AUC, confidence interval, and P-value, despite using different proteins and outcomes.

↳ Results, Fig. 5C and Fig. 5E

#methodological rigour

Model selection precedes performance evaluation

Proteins were filtered by outcome correlation and models were dredged by AICc, while validation was absent for plasma models and was not shown to encompass feature selection for the CSF models.

↳ Methods, Statistical Analysis; Results, Fig. 3 and Fig. 5

#methodological rigour

Progression evidence lacks independent validation

The prognostic analyses use few events, internally selected cut-offs, and no strong clinical-only comparator or external cohort. PIRMA and SPMS conversion also overlap substantially.

↳ Results, Fig. 4–5; Discussion, limitations

Does this match your read? Add your assessment ↓

Nabu Commentary

The study's strongest foundation is its treatment-naïve baseline cohort, standardized biofluid handling, and long follow-up for clinically relevant progression outcomes. Its cross-sectional CSF findings are supported by adjusted, FDR-controlled analyses, but much of that profile confirms existing biomarker literature. Confidence falls sharply for the prognostic models because proteins and cut-offs were selected internally, plasma models were not validated, and no clinical-only prognostic comparator was presented. The identical AUC, confidence interval, and P-value reported for two different plasma models, together with other Results–Discussion inconsistencies, requires correction before the headline performance claims can be relied upon.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.5±0.2

Contribution
3.1

The study combines baseline CSF and plasma proteomics with long clinical follow-up and nominates KITLG as a potentially novel progression-associated marker. The advance remains incremental because much of the CSF profile is confirmatory and the prognostic findings have not been externally validated.

Abstract; Results, Fig. 1–5; Discussion, opening two paragraphs

These results are largely confirmatory

Methodological Rigour
1.9

Standardized sample handling, FDR-controlled expression analysis, covariate-adjusted Cox models, and internal cross-validation support the exploratory design. However, outcome-informed feature selection was not nested within validation, the plasma models were evaluated in the selection cohort, and no clinical prognostic baseline was tested.

Methods, NULISA Proteomic Analysis and Statistical Analysis; Results, Fig. 3–5

the single best-performing model was selected

Reporting
3.1

The article follows a coherent progression from cohort definition through proteomic comparison and prognostic analysis. Predictive language in the Abstract and Discussion overstates small internally selected models, while references to IKBKG, PTX3, and an unreported log-rank test interrupt the evidence chain.

Abstract; Discussion, KITLG paragraph, intrathecal-indices paragraph, and summary

KITLG as a promising biomarker for predicting disease progression and PIRMA

Positioning
2.8

The Discussion engages prior CSF and plasma proteomic work, including a contrasting large plasma study, and acknowledges sample size and external-validation needs. It does not directly address selection-induced optimism in the reported AUCs or the substantial overlap between PIRMA and SPMS conversion.

Discussion, opening literature comparison and limitations paragraphs; Results, PIRMA section

external validation in independent cohorts is needed

Reliability

Caveats4 of 4 checks


Results checkNoted
  • A model selection analysis identified a two-protein logistic regression model including interleukin 1 beta and interleukin 36 gamma as the best-performing combination (area under the curve = 0.990): "To evaluate their predictive potential, we performed a model selection analysis, which identified a two-protein logistic regression model including IL1B and IL36G as the best-performing combination (AUC = 0.990, 95% CI: 0.961–1.000, P < 0.001), slightly outperforming the individual proteins" (Results, Plasma concentrations of two proteins are associated with conversion to SPMS, Fig. 5C) vs "From these seven altered proteins, we could identify a prediction model (Best Model) for PIRMA consisting of CCL27, NGF and SPP1 outperforming any of the individual proteins alone (AUC = 0.990, 95% CI: 0.961–1.000, P < 0.001)" (Results, Plasma concentrations of two proteins are associated with conversion to SPMS, Fig. 5E). The SPMS-conversion and PIRMA models report identical AUCs, confidence limits and P-value bounds despite different predictors and outcomes, but those equalities alone do not establish a transcription error. → Effect on result unclear
Reporting and transparencyNoted

The Discussion introduces an unreported IKBKG result and a log-rank analysis not described in Methods or Results. Funding, conflict-of-interest and code-availability statements are absent from the supplied text; the conventional data-on-request statement is not itself a reliability concern.

Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated

Reference IntegrityClean

50 references in manuscript 50 of 50 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Multiple sclerosis
Type of advanceEmpirical
Route to useSuggested
AdvanceAdvances
BeneficiariesSmall
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The predictive performance of KITLG was demonstrated once in a single small exploratory cohort with internal cross-validation, and the authors state external validation in independent cohorts is still needed.

From the paper
“plasma IL1B could serve as a potential biomarker for identifying RRMS patients at risk of transitioning to SPMS”

The paper names prognostic biomarker use and therapeutic targeting of IL1B/NLRP3, but does not specify which profession, organisation or clinical setting would act on the findings.

Pathway

Neurologists could use validated CSF KITLG and plasma IL1B/IL36G tests to stratify RRMS patients at risk of progression and guide earlier treatment decisions.

Barrier

The findings come from a modest single-centre exploratory cohort and require confirmation in independent cohorts and clinical settings before any prognostic test could be adopted.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Neurofilament light chain and glial fibrillary acidic protein as biomarkers of peripheral nervous system involvement in multiple sclerosis: diagnostic and prognostic evaluation

    Flintere-Flinte, Krutovs, Pantelejeva, et al. · 2026 · Clinical medicine

    Primary claim

    Serum NfL was found to be a reliable marker of disease activity and progression.

    Tentative
    Evidence Score
    2.7±0.1
    Reliability
    Caveats
  2. Kappa Free Light Chains Reflect Treatment Response and Progression Independent of Focal Inflammation in Multiple Sclerosis

    Rosenstein, Axelsson, Johnsson, et al. · 2026 · Clinical medicine

    Primary claim

    Natalizumab appears to reduce intrathecal KFLC synthesis, and a decline in KFLC index may reflect effective suppression of CNS humoral immunity.

    Supported
    Evidence Score
    3.0±0.2
    Reliability
    Caveats
  3. DNA damage burden causes selective CUX2 neuron loss in neuroinflammation

    Morcom, Xia, Xu, et al. · 2026 · Basic medicine

    Primary claim

    These findings indicate that DNA damage burden and inadequate repair in CUX2+ L2/3ENs contributes to selective vulnerability in neuroinflammatory injury.

    Supported
    Evidence Score
    3.1±0.1
    Reliability
    No concerns

How the rubric works →